CTOs on the Move

Cybrexa

www.cybrexa.com

 
Cybrexa is a clinical-stage oncology biotechnology company developing novel antigen-independent peptide drug conjugates (ADCs) aimed at combatting a range of cancer types, including ovarian, breast and non-small cell lung cancer. With the potential to disrupt the standard of care, the Cybrexa alphalex™ technology is a novel antigen-independent peptide drug conjugate (PDC) platform that enables targeted delivery of highly potent anticancer treatments and aims to revolutionize the standard of care in oncology. The platform consists of a pHLIP® peptide, linker, and small molecule anti-cancer agent. pHLIP® peptides are a family of pH-Low Insertion Peptides that target acidic cell surfaces. pHLIP® was developed at ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.cybrexa.com
  • 5 Science Park 395 Winchester Avenue
    New Haven, CT USA 06511
  • Phone: 860.717.2731

Executives

Name Title Contact Details
Jaya Gautam
Senior Vice President of Technical Operations Profile

Funding

Cybrexa raised $13.4M on 06/21/2019
Cybrexa raised $25M on 03/10/2021

Similar Companies

Epicentre Technologies Corp

Epicentre Technologies Corp is a Madison, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Oncothyreon

Oncothyreon is a Seattle, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Lumen Bioscience

Lumen Bioscience develops oral antibody therapeutics.

Luknova

Luknova is a Mansfield, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

ZS Pharma

ZS Pharma is using innovative technology to change the landscape of disease management. At ZS Pharma, we have a vision—to transform the status quo and improve the options for patients and physicians facing difficult-to-manage conditions such as ion imbalances. We are committed to taking on medicine’s challenges with a new outlook, and we believe that real progress comes with a real promise to approach things in a novel way.